[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100603790":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":20,"locations":30,"responsibleParty":47,"collaborators":10,"id":49,"slug":50,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":10,"eligibilityCriteria":54,"healthyVolunteers":51,"sex":55,"minAge":56,"maxAge":10,"enrollmentInfo":57,"targetDuration":10,"studyType":60,"phases":10,"briefSummary":61,"conditions":62,"keywords":10,"overallStatus":64,"whyStopped":10,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":74},{"fullName":5,"class":6},"Institute of Hematology & Blood Diseases Hospital, China","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Participants with CMV Infection",null,"Participants will receive maribavirv tablets, 400 mg, orally twice a day(bid) for up to 8 weeks treatment period.",[13],"Drug: maribavir",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DRUG","maribavir","Maribavir tablets are administered orally at a dose of 0.4 g per administration (2 tablets of 0.2 g each), twice daily. The recommended duration of treatment is 8 weeks; however, the specific treatment duration should be individualized based on the clinical characteristics of each patient.",[9],[21,26],{"name":22,"role":23,"phone":24,"phoneExt":10,"email":25},"Jiang Erlie, doctor","CONTACT","+86-15122538106","jiangerlie@ihcams.ac.cn",{"name":27,"role":23,"phone":28,"phoneExt":10,"email":29},"Pang Aiming, doctor","+86-13820398091","pangaiming@ihcams.ac.cn",[31],{"facility":32,"status":10,"city":33,"state":34,"zip":10,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences","Tianjin","Tianjin Municipality","China","CN",{"type":38,"coordinates":39},"Point",[40,41],117.17667,39.14222,{"lat":41,"lon":40},[44],{"name":45,"role":23,"phone":24,"phoneExt":10,"email":46},"Erlie Jiang","jiangerlie@ihcmas.ac.cn",{"type":48,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100603790","a-prospective-single-arm-observational-study-of-maribavir-for-the-treatment-of-post-hematopoietic-stem-cell-transplantation-cytomegalovirus-infection-100603790",false,"NCT07141095","A Prospective Single-Arm Observational Study of Maribavir for the Treatment of Post Hematopoietic Stem Cell Transplantation Cytomegalovirus Infection","Inclusion Criteria:\n\n* Hematopoietic Stem Cell Transplant Recipients\n\n  1. Adult patients with an expected survival of ≥4 weeks.\n  2. Confirmed CMV infection, including CMV viremia and CMV disease.\n  3. Fully understand the content of the trial, voluntarily participate and complete the trial, and voluntarily sign the informed consent form.\n\nExclusion Criteria:\n\n* Participants who meet any of the following criteria are not eligible for this study:\n\n  1. Patients currently participating in other CMV-related clinical studies, such as those receiving anti-CMV drug treatment or involved in CMV vaccine clinical studies.\n  2. At screening, liver function tests show: AST \\> 5×ULN, or ALT \\> 5×ULN, or total bilirubin ≥ 3.0×ULN.\n  3. Patients with psychiatric disorders or severe psychological conditions that may affect the ability to provide informed consent or participate in follow-up consultations.\n  4. Participants deemed unsuitable for inclusion by the investigator.","ALL","12 Years",{"count":58,"type":59},17,"ESTIMATED","OBSERVATIONAL","The main aim of this study is to check the effectiveness and safety of maribavir for the treatment of CMV infection after HSCT in Chinese patients in real-world settings.\n\nThe participants will be treated with maribavir for up to 8 weeks.",[63],"Infections, Cytomegalovirus","NOT_YET_RECRUITING","2025-08-18",{"date":67,"type":68},"2025-08-26","ACTUAL",{"date":70,"type":59},"2025-09-25",{"date":72,"type":59},"2027-01-31",{"name":5,"class":6},1]